Abstract
Treatment with tumor necrosis factor α inhibitors is a risk factor for tuberculosis (TB). Despite previous treatment with isoniazid for latent TB, a 9-year-old girl with juvenile idiopathic arthritis developed disseminated TB after changing therapy with etanercept to adalimumab and after new contact with a smear-positive relative. Genotyping strain matches and susceptibility to isoniazid make reinfection more likely than reactivation in our patient.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adalimumab / adverse effects*
-
Adalimumab / therapeutic use
-
Anti-Inflammatory Agents / adverse effects*
-
Anti-Inflammatory Agents / therapeutic use
-
Arthritis, Juvenile / complications
-
Arthritis, Juvenile / drug therapy*
-
Child
-
Etanercept / adverse effects*
-
Etanercept / therapeutic use
-
Female
-
Genotype
-
Humans
-
Mycobacterium tuberculosis / genetics
-
Tuberculosis / etiology*
-
Tuberculosis / microbiology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Inflammatory Agents
-
Tumor Necrosis Factor-alpha
-
Adalimumab
-
Etanercept